-
Autor
Chan, Geoffrey 1 Cortes, Jorge E 1 DiRienzo, Christine G 1 Dombret, Hervé 1 Jeyakumar, Deepa 1 Jou, Erin 1 Liu, Xueli 1 Ma, Wendy 1 Mayer, Jiri 1 Merchant, Akil 1 Montesinos, Pau 1 Novak, Jan 1 O'Brien, Thomas 1 Robak, Tadeusz 1 Roh, Whijae 1 Sekeres, Mikkael A 1 Shaik, Naveed 1 Taussig, David C 1 Tomlinson, Benjamin 1 Wang, Jianxiang 1
-
Pracoviště
CIBERONC Instituto Carlos 3 Madrid Spain 1 Department of Clinical Hematology Ins... 1 Department of Haematology 3rd Faculty... 1 Department of Hematology Medical Univ... 1 Department of Hematology Oncology Don... 1 Department of Internal Medicine Hemat... 1 Department of Internal Medicine and H... 1 Division of Hematology Sylvester Comp... 1 Division of Hematology University Hos... 1 Division of Hematology and Cellular T... 1 Georgia Cancer Center Augusta GA USA 1 Hospital Universitari i Politècnic La... 1 Institut de Recherche Saint Louis Hôp... 1 Pfizer Inc Collegeville PA USA 1 Pfizer Oncology Pfizer Inc San Diego ... 1 The Royal Marsden Hospital London UK 1 University of California Irvine Chao ... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Chan, Geoffrey 1 Cortes, Jorge E 1 DiRienzo, Christine G 1 Dombret, Hervé 1 Jeyakumar, Deepa 1 Jou, Erin 1 Liu, Xueli 1 Ma, Wendy 1 Mayer, Jiri 1 Merchant, Akil 1 Montesinos, Pau 1 Novak, Jan 1 O'Brien, Thomas 1 Robak, Tadeusz 1 Roh, Whijae 1 Sekeres, Mikkael A 1 Shaik, Naveed 1 Taussig, David C 1 Tomlinson, Benjamin 1 Wang, Jianxiang 1
-
Pracoviště
CIBERONC Instituto Carlos 3 Madrid Spain 1 Department of Clinical Hematology Ins... 1 Department of Haematology 3rd Faculty... 1 Department of Hematology Medical Univ... 1 Department of Hematology Oncology Don... 1 Department of Internal Medicine Hemat... 1 Department of Internal Medicine and H... 1 Division of Hematology Sylvester Comp... 1 Division of Hematology University Hos... 1 Division of Hematology and Cellular T... 1 Georgia Cancer Center Augusta GA USA 1 Hospital Universitari i Politècnic La... 1 Institut de Recherche Saint Louis Hôp... 1 Pfizer Inc Collegeville PA USA 1 Pfizer Oncology Pfizer Inc San Diego ... 1 The Royal Marsden Hospital London UK 1 University of California Irvine Chao ... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
PubMed
37604981
DOI
10.1038/s41375-023-02001-z
Knihovny.cz E-zdroje
This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782-1.408; two-sided p = 0.749) and non-intensive (n = 325; HR 0.99; 95% CI: 0.768-1.289; two-sided p = 0.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration: ClinicalTrials.gov: NCT03416179.
- MeSH
- akutní myeloidní leukemie * MeSH
- anemie * farmakoterapie MeSH
- azacytidin terapeutické užití MeSH
- cytarabin MeSH
- daunomycin MeSH
- lidé MeSH
- nauzea farmakoterapie MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- randomizované kontrolované studie MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.